| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
9,286 |
7,379 |
$94K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
47,340 |
37,648 |
$73K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
4,548 |
3,795 |
$65K |
| 90832 |
Psychotherapy, 30 minutes with patient |
8,835 |
8,046 |
$28K |
| 0001A |
|
533 |
486 |
$17K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,223 |
3,987 |
$13K |
| 0002A |
|
368 |
355 |
$10K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
2,685 |
2,283 |
$10K |
| 99442 |
|
2,874 |
2,476 |
$10K |
| 90461 |
|
1,707 |
1,530 |
$9K |
| 0003A |
|
221 |
220 |
$9K |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
464 |
428 |
$8K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
9,120 |
7,466 |
$8K |
| 96160 |
|
895 |
820 |
$7K |
| 99441 |
|
7,563 |
6,593 |
$6K |
| G0101 |
Cervical or vaginal cancer screening; pelvic and clinical breast examination |
110 |
109 |
$2K |
| 90670 |
|
1,695 |
1,436 |
$2K |
| 90688 |
|
1,486 |
925 |
$2K |
| 90474 |
|
383 |
337 |
$1K |
| 90791 |
Psychiatric diagnostic evaluation |
839 |
825 |
$1K |
| 0031A |
|
30 |
18 |
$1K |
| 90651 |
|
2,170 |
1,815 |
$1K |
| 88141 |
|
138 |
120 |
$1K |
| 90834 |
Psychotherapy, 45 minutes with patient |
1,628 |
1,473 |
$887.71 |
| 97802 |
|
132 |
119 |
$871.90 |
| 90847 |
Family psychotherapy with the patient present, 50 minutes |
95 |
92 |
$732.96 |
| 90697 |
|
605 |
562 |
$732.90 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
2,248 |
1,950 |
$686.66 |
| 90620 |
|
989 |
780 |
$681.71 |
| 90734 |
|
1,487 |
1,204 |
$632.81 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
586 |
512 |
$598.30 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
300 |
299 |
$469.20 |
| 76830 |
Ultrasound, transvaginal |
14 |
13 |
$402.24 |
| 97803 |
|
73 |
73 |
$326.48 |
| 90680 |
|
348 |
305 |
$300.00 |
| 90674 |
|
136 |
132 |
$260.80 |
| 80305 |
|
2,131 |
1,731 |
$225.58 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
393 |
353 |
$163.87 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
153 |
147 |
$140.36 |
| 90681 |
|
68 |
67 |
$140.00 |
| 90694 |
|
453 |
371 |
$138.11 |
| G2010 |
Remote evaluation of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment |
35 |
24 |
$115.18 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
390 |
376 |
$100.42 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
460 |
389 |
$96.51 |
| 99421 |
|
796 |
675 |
$89.76 |
| 90687 |
|
249 |
223 |
$87.65 |
| 90746 |
|
14 |
14 |
$71.00 |
| 99050 |
|
1,389 |
1,085 |
$66.00 |
| 90686 |
|
1,232 |
837 |
$60.13 |
| 96127 |
|
1,351 |
1,286 |
$51.75 |
| 90715 |
|
847 |
675 |
$47.50 |
| 90633 |
|
1,615 |
1,409 |
$46.00 |
| 90700 |
|
515 |
449 |
$27.63 |
| 80354 |
|
135 |
98 |
$13.01 |
| 90707 |
|
1,085 |
907 |
$12.02 |
| 90658 |
|
115 |
109 |
$12.00 |
| 90716 |
|
1,245 |
1,044 |
$0.04 |
| 90696 |
|
341 |
287 |
$0.03 |
| 99406 |
|
769 |
613 |
$0.03 |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,460 |
1,311 |
$0.01 |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,437 |
1,950 |
$0.01 |
| 3008F |
|
31,317 |
24,911 |
$0.01 |
| 1000F |
|
17,619 |
13,743 |
$0.01 |
| 3077F |
|
3,487 |
2,802 |
$0.00 |
| 4004F |
|
1,527 |
1,246 |
$0.00 |
| 3015F |
|
156 |
117 |
$0.00 |
| 3078F |
|
15,055 |
11,824 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
515 |
386 |
$0.00 |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
355 |
309 |
$0.00 |
| 3725F |
|
4,011 |
3,304 |
$0.00 |
| 1159F |
|
644 |
559 |
$0.00 |
| 99408 |
|
3,424 |
2,712 |
$0.00 |
| 90648 |
|
30 |
25 |
$0.00 |
| 1160F |
|
618 |
362 |
$0.00 |
| 0518F |
|
12 |
12 |
$0.00 |
| 4013F |
|
781 |
489 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
210 |
202 |
$0.00 |
| 4551F |
|
511 |
499 |
$0.00 |
| 99401 |
|
94 |
77 |
$0.00 |
| 91300 |
|
607 |
560 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
15 |
15 |
$0.00 |
| 90710 |
|
45 |
41 |
$0.00 |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
133 |
122 |
$0.00 |
| 99001 |
|
26 |
26 |
$0.00 |
| 90649 |
|
61 |
61 |
$0.00 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
64 |
49 |
$0.00 |
| 90713 |
|
15 |
12 |
$0.00 |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
116 |
93 |
$0.00 |
| Q2038 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) |
190 |
170 |
$0.00 |
| 99173 |
|
122 |
113 |
$0.00 |
| 90756 |
|
39 |
37 |
$0.00 |
| 90672 |
|
19 |
18 |
$0.00 |
| 1033F |
|
13 |
13 |
$0.00 |
| 3050F |
|
61 |
41 |
$0.00 |
| 99215 |
Prolong outpt/office vis |
24 |
24 |
$0.00 |
| 90621 |
|
29 |
28 |
$0.00 |
| 90837 |
Psychotherapy, 53 minutes with patient |
33 |
29 |
$0.00 |
| 3079F |
|
4,337 |
3,642 |
$0.00 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
19 |
19 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
396 |
337 |
$0.00 |
| 4000F |
|
826 |
621 |
$0.00 |
| 1111F |
|
3,456 |
2,667 |
$0.00 |
| 3080F |
|
552 |
471 |
$0.00 |
| 99368 |
|
310 |
306 |
$0.00 |
| 1036F |
|
12,473 |
9,524 |
$0.00 |
| 3074F |
|
14,040 |
11,145 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
357 |
294 |
$0.00 |
| 1034F |
|
1,978 |
1,547 |
$0.00 |
| 90698 |
|
151 |
114 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
2,062 |
1,899 |
$0.00 |
| 1170F |
|
73 |
72 |
$0.00 |
| 3017F |
|
541 |
394 |
$0.00 |
| 1031F |
|
355 |
296 |
$0.00 |
| 3292F |
|
785 |
539 |
$0.00 |
| 3075F |
|
2,496 |
1,988 |
$0.00 |
| 1157F |
|
19 |
18 |
$0.00 |
| 90677 |
|
144 |
130 |
$0.00 |
| 3072F |
|
15 |
15 |
$0.00 |
| 3048F |
|
928 |
651 |
$0.00 |
| 88174 |
|
142 |
138 |
$0.00 |
| 90723 |
|
13 |
13 |
$0.00 |
| 1126F |
|
141 |
137 |
$0.00 |
| 3044F |
|
1,502 |
1,102 |
$0.00 |
| 3061F |
|
169 |
141 |
$0.00 |
| 80050 |
General health panel |
66 |
65 |
$0.00 |
| 2001F |
|
30 |
28 |
$0.00 |
| 90647 |
|
292 |
205 |
$0.00 |
| 3049F |
|
268 |
197 |
$0.00 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
40 |
34 |
$0.00 |
| 1030F |
|
362 |
325 |
$0.00 |
| 90619 |
|
110 |
105 |
$0.00 |
| 4086F |
|
28 |
28 |
$0.00 |
| 91301 |
|
32 |
32 |
$0.00 |
| H0001 |
Alcohol and/or drug assessment |
77 |
71 |
$0.00 |
| G8428 |
Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given |
23 |
15 |
$0.00 |
| 1123F |
|
53 |
50 |
$0.00 |
| 10004 |
|
54 |
54 |
$0.00 |
| 3014F |
|
30 |
30 |
$0.00 |
| 99443 |
|
23 |
19 |
$0.00 |
| 2000F |
|
19 |
19 |
$0.00 |
| 1125F |
|
147 |
136 |
$0.00 |
| 4010F |
|
26 |
25 |
$0.00 |
| 1035F |
|
19 |
12 |
$0.00 |